文献速递痛风与晶体性关节病

非诺贝特对原发性痛风患者肾功能的影响

Effects of fenofibrate therapy on renal function in primary gout patients.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该回顾性研究纳入983例接受非诺贝特治疗的痛风患者,10.2%在启动后6个月内出现血清肌酐升高≥0.3 mg/dl。慢性肾病(OR 2.39)和痛风石(OR 2.29)是独立风险预测因素;停药后65%患者肌酐升高逆转。

要点

  • 痛风患者使用非诺贝特后10.2%发生肌酐升高≥0.3 mg/dl。
  • 合并慢性肾病或痛风石者肾毒性风险更高。
  • 停药后65%患者肌酐升高可逆转。

核心结论

  • 非诺贝特相关肾毒性在痛风患者中较常见,尤其合并痛风石或慢性肾病者。

研究设计与样本

  • 回顾性队列研究,纳入2016年9月至2020年6月青岛大学附属医院痛风专病门诊983例接受非诺贝特治疗的痛风患者。

主要发现

  • 100例(10.2%)在非诺贝特启动后6个月内血清肌酐升高≥0.3 mg/dl。
  • 全队列肌酐变化中位数为0.11 mg/dl(IQR 0.03-0.20),肾毒性组为0.36(0.33-0.45)。
  • 多因素回归显示慢性肾病(OR 2.39,95%CI 1.48-3.86)和痛风石(OR 2.29,95%CI 1.39-3.78)是独立风险预测因素。
  • GAMM交互分析显示治疗期间肌酐暂时升高,但血清尿酸和甘油三酯下降。
  • 有停药记录者中65%患者肌酐升高在平均停药49天后逆转。

临床怎么用

  • 对痛风患者使用非诺贝特时应监测肾功能,尤其合并慢性肾病或痛风石者。

局限性

  • 观察性研究提示关联,非诺贝特在痛风中的潜在肾脏风险需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the incidence and potential risk factors for development of fenofibrate-associated nephrotoxicity in gout patients. METHODS: A total of 983 gout patients on fenofibrate treatment who visited the dedicated Gout Clinic at the Affiliated Hospital of Qingdao University between September 2016 and June 2020 were retrospectively enrolled from the electronic records system. Fenofibrate-associated nephrotoxicity was defined as an increase in serum creatinine (SCr) ≥0.3 mg/dl within 6 months of fenofibrate initiation. The change trend of SCr and uric acid levels during the treatment period were assessed by a generalised additive mixed model (GAMM). Multivariate analysis was performed for risk factors affecting elevated SCr. RESULTS: A total of 100 (10.2%) patients experienced an increase in SCr ≥0.3 mg/dl within 6 months after fenofibrate initiation. The median change of SCr in the whole cohort was 0.11 mg/dl [interquartile range (IQR) 0.03-0.20], whereas it was 0.36 (0.33-0.45) in the fenofibrate-associated nephrotoxicity group. In a multivariable regression model, chronic kidney disease (CKD) [odds ratio (OR) 2.39 (95% CI 1.48, 3.86)] and tophus [OR 2.29 (95% CI 1.39, 3.78)] were identified to be risk predictors, independent of measured covariates, of fenofibrate-associated nephrotoxicity. During the treatment period, although SCr temporarily increased, serum urate and triglyceride concentrations decreased using the interaction analysis of GAMM. Of those with fenofibrate withdrawal records, the SCr increase in 65% of patients was reversed after an average of 49 days off the drug. CONCLUSIONS: This observational study implied that fenofibrate-associated nephrotoxicity occurs frequently in gout patients, especially in patients with tophi or CKD. The potential renal risks of fenofibrate usage in gout needs additional research.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Li X, Sun W, Lu J, et al. Effects of fenofibrate therapy on renal function in primary gout patients. Rheumatology (Oxford). 2021. PMID: 33704429. doi:10.1093/rheumatology/keab231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。